H.B. Fuller yesterday brushed aside a very public campaign from Cleveland-area investor Ancora by striking a deal to buy U.K. medical-products maker Advanced Medical Solutions in an all-cash transaction valued at about £715 million, or roughly $870 million. The adhesives maker says the purchase will broaden its medical-adhesives business and speed up a strategic shift toward higher-margin health markets, even as Ancora, based in Mayfield Heights, had urged Fuller to focus on paying down debt instead of pulling the trigger on a large overseas acquisition.
Deal terms and strategic logic
The offer of 285 pence per share values AMS at about £715 million and is expected to deliver roughly $55 million in run-rate synergies by 2031, according to Business Wire. Fuller says the deal should add roughly $300 million of revenue and significantly expand its medical-adhesives platform, calling the acquisition “a rare opportunity” to advance the company’s portfolio. Reuters reports that the transaction is expected to close by the end of 2026, subject to customary approvals.
Ancora pushes back
Ancora publicly blasted the proposal in a late-May letter, arguing the deal would push Fuller’s leverage above 4.0x net debt to pro-forma adjusted EBITDA and that management had drifted away from earlier promises to prioritize deleveraging, per Ancora’s release. Nasdaq carries Ancora’s letter, while local coverage from Crain's Cleveland notes the dispute pits the Mayfield Heights investor against Fuller’s leadership in St. Paul. Ancora, which says it owns more than 2% of Fuller, urged the board to slam the brakes on the AMS pursuit and instead launch a full strategic review.
Investor reaction and leverage questions
Traders did not exactly throw a party. Fuller’s shares fell as investors worried that the purchase would increase debt and temporarily push the company above its target leverage range, according to market coverage from Investing.com. On an earnings call, management acknowledged the leverage impact but described AMS as a time-sensitive strategic fit that should still allow Fuller to work its way back toward lower debt levels over time, according to a transcript reported by Benzinga. That tug-of-war between chasing growth and keeping the balance sheet tidy is now front and center for shareholders.
What happens next
The acquisition still needs AMS shareholder approval and regulatory clearances. Fuller says the deal is backed by committed financing and that it expects to return to its target leverage range within roughly two years, according to the company announcement. MarketScreener hosts the formal Rule 2.7 announcement and related filings. In Cleveland, Ancora’s objections have thrown a bright local spotlight on Fuller’s capital strategy, and the question now is whether this debt-fueled push into medical products will vindicate management’s bet or simply deepen the rift with some of its investors.
